Osteoporotic vertebral compression fracture (OVCF) patients had a proportion of secondary fractures after percutaneous vertebroplasty (PVP). Denosumab and zoledronate acid is both effective to prevent bone loss for OVCF postmenopausal women. However, trial evidence comparing effect of denosumab vs zoledronate after PVP was unknown. The study aims to assess the efficiency of denosumab vs zoledronate for OVCF patients bone mineral density (BMD), bone turnover markers (BTMs), secondary fracture and adverse events after PVP.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Lumbar bone mineral density(BMD)
Timeframe: up to 12 months
Total hip BMD
Timeframe: up to 12 months
Femoral neck BMD
Timeframe: up to 12 months
Procollagen type 1 n-terminal propeptide (P1NP)
Timeframe: up to 12 months
C-terminal cross-linked type 1 collagen terminal peptide (CTX)
Timeframe: up to 12 months
Visual analog scale (VAS) back
Timeframe: up to 12 months